**5. Conclusions**

Although the use of liposome-supported peritoneal dialysis remains in the preclinical phase, there are promising signs for its potential use in areas of unmet clinical need in the future. The use of LSPD to increase ammonia extraction is the indication that is

furthest along the development pipeline. The use of liposomes to improve the clearance of protein-bound uraemic toxins in renal failure is a nascent investigational field, which could potentially augment treatments for a large population with a chronic illness. Experiments in which liposomes are used in dialysate appear to mitigate the problems encountered using intravenous liposomes and traditional dialysis techniques in animal models for specific intoxications. It is conceivable that liposomes will be repurposed from the role of pharmaceutical vectors to gain further indications as clinically useful nanomedical antidotes/treatments within the next decade.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
